{"id":2670,"date":"2025-10-22T10:40:05","date_gmt":"2025-10-22T08:40:05","guid":{"rendered":"https:\/\/okuvision.de\/retinitis-pigmentosa-therapie\/"},"modified":"2026-05-21T13:47:56","modified_gmt":"2026-05-21T11:47:56","slug":"retinitis-pigmentosa-therapie","status":"publish","type":"page","link":"https:\/\/okuvision.de\/fr\/retinitis-pigmentosa-therapie\/","title":{"rendered":"Th\u00e9rapie et traitement"},"content":{"rendered":"

[vc_row unlock_row_content=\u00a0\u00bbyes\u00a0\u00bb row_height_percent=\u00a0\u00bb0″ override_padding=\u00a0\u00bbyes\u00a0\u00bb h_padding=\u00a0\u00bb0″ top_padding=\u00a0\u00bb0″ bottom_padding=\u00a0\u00bb0″ back_color=\u00a0\u00bbcolor-206913″ overlay_alpha=\u00a0\u00bb50″ gutter_size=\u00a0\u00bb3″ column_width_percent=\u00a0\u00bb100″ shift_y=\u00a0\u00bb0″ z_index=\u00a0\u00bb0″ content_parallax=\u00a0\u00bb0″ uncode_shortcode_id=\u00a0\u00bb126459″ back_color_type=\u00a0\u00bbuncode-palette\u00a0\u00bb][vc_column width=\u00a0\u00bb1\/1″]\n

\n \n \n
<\/div>\n
<\/div>\n \n \n
\n \n
\n
\n \n \n

\n R\u00e9tinite pigmentaire : aper\u00e7u des options th\u00e9rapeutiques <\/h1>\n \n
\n
\n

Quelles sont les options disponibles \u2013 objectifs r\u00e9alistes, importance de la th\u00e9rapie TES (OkuStim\u00ae) et distinction par rapport aux approches g\u00e9niques et de r\u00e9\u00e9ducation.<\/p>\n <\/div>\n \n <\/div>\n \n \n <\/div>\n \n \n

\n \"Okuvision <\/div>\n <\/div>\n \n <\/div>\n \n<\/div>\n\n\n[\/vc_column][\/vc_row][vc_row row_height_percent=\u00a0\u00bb0″ override_padding=\u00a0\u00bbyes\u00a0\u00bb h_padding=\u00a0\u00bb2″ top_padding=\u00a0\u00bb3″ bottom_padding=\u00a0\u00bb0″ overlay_alpha=\u00a0\u00bb50″ gutter_size=\u00a0\u00bb3″ column_width_percent=\u00a0\u00bb100″ shift_y=\u00a0\u00bb0″ z_index=\u00a0\u00bb0″ content_parallax=\u00a0\u00bb0″ uncode_shortcode_id=\u00a0\u00bb176312″][vc_column width=\u00a0\u00bb1\/1″][vc_row_inner][vc_column_inner width=\u00a0\u00bb2\/3″][vc_custom_heading text_font=\u00a0\u00bbfont-714446″ text_size=\u00a0\u00bbfontsize-914237″ text_weight=\u00a0\u00bb300″ uncode_shortcode_id=\u00a0\u00bb482476″]Objectifs th\u00e9rapeutiques : ce qui est r\u00e9alisable de mani\u00e8re r\u00e9aliste[\/vc_custom_heading][\/vc_column_inner][vc_column_inner column_width_percent=\u00a0\u00bb100″ gutter_size=\u00a0\u00bb3″ overlay_alpha=\u00a0\u00bb50″ shift_x=\u00a0\u00bb0″ shift_y=\u00a0\u00bb0″ shift_y_down=\u00a0\u00bb0″ z_index=\u00a0\u00bb0″ medium_visibility=\u00a0\u00bbyes\u00a0\u00bb medium_width=\u00a0\u00bb0″ mobile_visibility=\u00a0\u00bbyes\u00a0\u00bb mobile_width=\u00a0\u00bb0″ width=\u00a0\u00bb1\/3″ uncode_shortcode_id=\u00a0\u00bb542260″][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner column_width_percent=\u00a0\u00bb100″ gutter_size=\u00a0\u00bb3″ overlay_alpha=\u00a0\u00bb50″ shift_x=\u00a0\u00bb0″ shift_y=\u00a0\u00bb0″ shift_y_down=\u00a0\u00bb0″ z_index=\u00a0\u00bb0″ medium_visibility=\u00a0\u00bbyes\u00a0\u00bb medium_width=\u00a0\u00bb0″ mobile_visibility=\u00a0\u00bbyes\u00a0\u00bb mobile_width=\u00a0\u00bb0″ width=\u00a0\u00bb1\/3″ uncode_shortcode_id=\u00a0\u00bb163215″][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb2\/3″][vc_column_text uncode_shortcode_id=\u00a0\u00bb206887″]La r\u00e9tinite pigmentaire (RP) ne peut pas \u00eatre gu\u00e9rie aujourd\u2019hui. La litt\u00e9rature scientifique recommande d\u2019orienter la th\u00e9rapie et la prise en charge vers trois objectifs :
\n(1) ralentir la perte de fonction
\n(2) traiter les complications (par exemple, opacit\u00e9 du cristallin, \u0153d\u00e8me maculaire) conform\u00e9ment aux directives et
\n(3) assurer la qualit\u00e9 de vie par la r\u00e9\u00e9ducation et les aides techniques. Ces objectifs refl\u00e8tent le paysage actuel des preuves et des soins.1<\/sup>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row row_height_percent=\u00a0\u00bb0″ override_padding=\u00a0\u00bbyes\u00a0\u00bb h_padding=\u00a0\u00bb2″ top_padding=\u00a0\u00bb3″ bottom_padding=\u00a0\u00bb3″ overlay_alpha=\u00a0\u00bb50″ gutter_size=\u00a0\u00bb3″ column_width_percent=\u00a0\u00bb100″ shift_y=\u00a0\u00bb0″ z_index=\u00a0\u00bb0″ content_parallax=\u00a0\u00bb0″ uncode_shortcode_id=\u00a0\u00bb137928″][vc_column width=\u00a0\u00bb1\/1″][vc_row_inner][vc_column_inner width=\u00a0\u00bb2\/3″][vc_custom_heading text_font=\u00a0\u00bbfont-714446″ text_size=\u00a0\u00bbfontsize-914237″ text_weight=\u00a0\u00bb300″ uncode_shortcode_id=\u00a0\u00bb971846″]Le diagnostic d\u2019abord : qui profite de quelle option ?[\/vc_custom_heading][\/vc_column_inner][vc_column_inner column_width_percent=\u00a0\u00bb100″ gutter_size=\u00a0\u00bb3″ overlay_alpha=\u00a0\u00bb50″ shift_x=\u00a0\u00bb0″ shift_y=\u00a0\u00bb0″ shift_y_down=\u00a0\u00bb0″ z_index=\u00a0\u00bb0″ medium_visibility=\u00a0\u00bbyes\u00a0\u00bb medium_width=\u00a0\u00bb0″ mobile_visibility=\u00a0\u00bbyes\u00a0\u00bb mobile_width=\u00a0\u00bb0″ width=\u00a0\u00bb1\/3″ uncode_shortcode_id=\u00a0\u00bb542260″][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner column_width_percent=\u00a0\u00bb100″ gutter_size=\u00a0\u00bb3″ overlay_alpha=\u00a0\u00bb50″ shift_x=\u00a0\u00bb0″ shift_y=\u00a0\u00bb0″ shift_y_down=\u00a0\u00bb0″ z_index=\u00a0\u00bb0″ medium_visibility=\u00a0\u00bbyes\u00a0\u00bb medium_width=\u00a0\u00bb0″ mobile_visibility=\u00a0\u00bbyes\u00a0\u00bb mobile_width=\u00a0\u00bb0″ width=\u00a0\u00bb1\/3″ uncode_shortcode_id=\u00a0\u00bb163215″][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb2\/3″][vc_column_text uncode_shortcode_id=\u00a0\u00bb153563″]La RP est h\u00e9r\u00e9ditaire et g\u00e9n\u00e9tiquement diversifi\u00e9e. Une clarification g\u00e9n\u00e9tique peut orienter la th\u00e9rapie (par exemple, tester une th\u00e9rapie g\u00e9nique pour certaines mutations), aide au conseil et facilite l\u2019acc\u00e8s aux \u00e9tudes. Parall\u00e8lement, seule une petite proportion des personnes concern\u00e9es dispose aujourd\u2019hui d\u2019une option de th\u00e9rapie g\u00e9nique approuv\u00e9e (par exemple, les formes associ\u00e9es au g\u00e8ne RPE65).1<\/sup> <\/p>\n

Important pour le suivi de l\u2019\u00e9volution :<\/strong> dans la RP, la surface du champ visuel diminue typiquement de mani\u00e8re exponentielle ; les \u00e9tudes font \u00e9tat de d\u00e9clins annuels moyens (ADR) de l\u2019ordre de ~5 \u00e0 17 %, d\u00e9pendant notamment de la m\u00e9thode de mesure et du niveau initial. Par cons\u00e9quent, les mesures doivent, dans la mesure du possible, \u00eatre r\u00e9p\u00e9t\u00e9es de mani\u00e8re standardis\u00e9e (m\u00eame proc\u00e9dure, conditions similaires).[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row row_height_percent=\u00a0\u00bb0″ override_padding=\u00a0\u00bbyes\u00a0\u00bb h_padding=\u00a0\u00bb2″ top_padding=\u00a0\u00bb3″ bottom_padding=\u00a0\u00bb3″ overlay_alpha=\u00a0\u00bb50″ gutter_size=\u00a0\u00bb3″ column_width_percent=\u00a0\u00bb100″ shift_y=\u00a0\u00bb0″ z_index=\u00a0\u00bb0″ content_parallax=\u00a0\u00bb0″ uncode_shortcode_id=\u00a0\u00bb103130″][vc_column width=\u00a0\u00bb1\/1″][vc_custom_heading text_font=\u00a0\u00bbfont-714446″ text_size=\u00a0\u00bbfontsize-914237″ text_weight=\u00a0\u00bb300″ uncode_shortcode_id=\u00a0\u00bb173997″]La TES (OkuStim\u00ae) dans les \u00e9tudes \u2013 explication br\u00e8ve[\/vc_custom_heading][vc_row_inner][vc_column_inner column_width_percent=\u00a0\u00bb100″ gutter_size=\u00a0\u00bb3″ overlay_alpha=\u00a0\u00bb50″ shift_x=\u00a0\u00bb0″ shift_y=\u00a0\u00bb0″ shift_y_down=\u00a0\u00bb0″ z_index=\u00a0\u00bb0″ medium_visibility=\u00a0\u00bbyes\u00a0\u00bb medium_width=\u00a0\u00bb0″ mobile_visibility=\u00a0\u00bbyes\u00a0\u00bb mobile_width=\u00a0\u00bb0″ width=\u00a0\u00bb1\/3″ uncode_shortcode_id=\u00a0\u00bb184318″][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb2\/3″][vc_column_text text_lead=\u00a0\u00bbyes\u00a0\u00bb uncode_shortcode_id=\u00a0\u00bb887171″]Qu\u2019est-ce que la TES ? La stimulation \u00e9lectrique transcorn\u00e9enne (TES) stimule la r\u00e9tine via de faibles courants alternatifs \u00e0 la surface de l\u2019\u0153il. L\u2019objectif est d\u2019activer les m\u00e9canismes de protection cellulaire afin de pr\u00e9server plus longtemps la fonction visuelle existante.[\/vc_column_text][vc_custom_heading heading_semantic=\u00a0\u00bbh3″ text_size=\u00a0\u00bbh3″ uncode_shortcode_id=\u00a0\u00bb197836″]Que disent les preuves cliniques ?[\/vc_custom_heading][vc_column_text uncode_shortcode_id=\u00a0\u00bb134063″]Une \u00e9valuation interventionnelle randomis\u00e9e de 12 mois avec application monoculaire (hebdomadaire, 30 min) a montr\u00e9 : la perte de la surface du champ visuel (VFA) \u00e9tait plus faible dans l\u2019\u0153il trait\u00e9 que dans l\u2019\u0153il partenaire ou l\u2019\u0153il t\u00e9moin (sham) ; de plus, il existait une relation dose-effet (intensit\u00e9 de courant plus \u00e9lev\u00e9e \u2192 effet plus marqu\u00e9). Tol\u00e9rance : dans les analyses publi\u00e9es, des troubles principalement l\u00e9gers et transitoires ont \u00e9t\u00e9 d\u00e9crits (par exemple, s\u00e9cheresse oculaire) ; les \u00e9v\u00e9nements graves li\u00e9s \u00e0 la th\u00e9rapie n\u2019\u00e9taient pas typiques, et aucune augmentation des \u00e9v\u00e9nements graves d\u00e9pendante de l\u2019intensit\u00e9 du courant n\u2019a \u00e9t\u00e9 observ\u00e9e.3<\/sup>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row row_height_percent=\u00a0\u00bb0″ override_padding=\u00a0\u00bbyes\u00a0\u00bb h_padding=\u00a0\u00bb2″ top_padding=\u00a0\u00bb2″ bottom_padding=\u00a0\u00bb3″ overlay_alpha=\u00a0\u00bb50″ gutter_size=\u00a0\u00bb3″ column_width_percent=\u00a0\u00bb100″ shift_y=\u00a0\u00bb0″ z_index=\u00a0\u00bb0″ content_parallax=\u00a0\u00bb0″ cvc_pattern_bottom_left=\u00a0\u00bbpattern\u00a0\u00bb uncode_shortcode_id=\u00a0\u00bb193115″][vc_column column_width_percent=\u00a0\u00bb100″ align_horizontal=\u00a0\u00bbalign_center\u00a0\u00bb gutter_size=\u00a0\u00bb3″ overlay_alpha=\u00a0\u00bb50″ shift_x=\u00a0\u00bb0″ shift_y=\u00a0\u00bb0″ shift_y_down=\u00a0\u00bb0″ z_index=\u00a0\u00bb0″ medium_width=\u00a0\u00bb0″ mobile_width=\u00a0\u00bb0″ width=\u00a0\u00bb1\/1″ uncode_shortcode_id=\u00a0\u00bb153108″][vc_single_image media=\u00a0\u00bb2948″ media_width_percent=\u00a0\u00bb100″ uncode_shortcode_id=\u00a0\u00bb103588″][vc_column_text uncode_shortcode_id=\u00a0\u00bb139692″]CONCLUSION :<\/strong> la TES ne gu\u00e9rit pas la RP, mais peut, selon les \u00e9tudes, ralentir la perte du champ visuel. Pour savoir si la TES vous convient, consultez votre ophtalmologiste \u2013 y compris pour les objectifs, l\u2019intensit\u00e9 de courant appropri\u00e9e et les contr\u00f4les standardis\u00e9s.2,3<\/sup>[\/vc_column_text][\/vc_column][\/vc_row][vc_row row_height_percent=\u00a0\u00bb0″ override_padding=\u00a0\u00bbyes\u00a0\u00bb h_padding=\u00a0\u00bb2″ top_padding=\u00a0\u00bb3″ bottom_padding=\u00a0\u00bb0″ overlay_alpha=\u00a0\u00bb50″ gutter_size=\u00a0\u00bb3″ column_width_percent=\u00a0\u00bb100″ shift_y=\u00a0\u00bb0″ z_index=\u00a0\u00bb0″ content_parallax=\u00a0\u00bb0″ uncode_shortcode_id=\u00a0\u00bb100668″][vc_column width=\u00a0\u00bb1\/1″][vc_row_inner][vc_column_inner width=\u00a0\u00bb2\/3″][vc_custom_heading text_font=\u00a0\u00bbfont-714446″ text_size=\u00a0\u00bbfontsize-914237″ text_weight=\u00a0\u00bb300″ uncode_shortcode_id=\u00a0\u00bb829882″]Distinction : autres orientations th\u00e9rapeutiques dans la recherche[\/vc_custom_heading][\/vc_column_inner][vc_column_inner column_width_percent=\u00a0\u00bb100″ gutter_size=\u00a0\u00bb3″ overlay_alpha=\u00a0\u00bb50″ shift_x=\u00a0\u00bb0″ shift_y=\u00a0\u00bb0″ shift_y_down=\u00a0\u00bb0″ z_index=\u00a0\u00bb0″ medium_visibility=\u00a0\u00bbyes\u00a0\u00bb medium_width=\u00a0\u00bb0″ mobile_visibility=\u00a0\u00bbyes\u00a0\u00bb mobile_width=\u00a0\u00bb0″ width=\u00a0\u00bb1\/3″ uncode_shortcode_id=\u00a0\u00bb542260″][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner column_width_percent=\u00a0\u00bb100″ gutter_size=\u00a0\u00bb3″ overlay_alpha=\u00a0\u00bb50″ shift_x=\u00a0\u00bb0″ shift_y=\u00a0\u00bb0″ shift_y_down=\u00a0\u00bb0″ z_index=\u00a0\u00bb0″ medium_visibility=\u00a0\u00bbyes\u00a0\u00bb medium_width=\u00a0\u00bb0″ mobile_visibility=\u00a0\u00bbyes\u00a0\u00bb mobile_width=\u00a0\u00bb0″ width=\u00a0\u00bb1\/3″ uncode_shortcode_id=\u00a0\u00bb163215″][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb2\/3″][vc_custom_heading heading_semantic=\u00a0\u00bbh3″ text_size=\u00a0\u00bbh3″ uncode_shortcode_id=\u00a0\u00bb129666″]Th\u00e9rapie g\u00e9nique (par exemple, RPE65) \u2013 pour qui est-elle adapt\u00e9e ?[\/vc_custom_heading][vc_column_text uncode_shortcode_id=\u00a0\u00bb135938″]Pour un petit sous-groupe pr\u00e9sentant des mutations RPE65, une th\u00e9rapie g\u00e9nique est disponible ; pour la majorit\u00e9 des formes de RP, il n\u2019existe pas encore d\u2019option approuv\u00e9e. Ici, les \u00e9tudes cliniques testant l\u2019efficacit\u00e9 et la s\u00e9curit\u00e9 de nouvelles approches sont d\u00e9terminantes.1 <\/sup>[\/vc_column_text][vc_custom_heading heading_semantic=\u00a0\u00bbh3″ text_size=\u00a0\u00bbh3″ uncode_shortcode_id=\u00a0\u00bb187992″]Optog\u00e9n\u00e9tique, remplacement cellulaire, implants \u2013 qu\u2019en est-il des \u00e9tudes ?[\/vc_custom_heading][vc_column_text uncode_shortcode_id=\u00a0\u00bb143716″]Les proc\u00e9d\u00e9s optog\u00e9n\u00e9tiques, les th\u00e9rapies cellulaires et les implants r\u00e9tiniens font l\u2019objet de recherches scientifiques. Ils visent \u00e0 r\u00e9activer ou \u00e0 compl\u00e9ter la fonction r\u00e9tinienne \u2013 jusqu\u2019\u00e0 pr\u00e9sent principalement dans le cadre d\u2019\u00e9tudes avec des indications restreintes.4 <\/sup>[\/vc_column_text][vc_custom_heading heading_semantic=\u00a0\u00bbh3″ text_size=\u00a0\u00bbh3″ uncode_shortcode_id=\u00a0\u00bb162587″]Traitement des maladies concomitantes et r\u00e9\u00e9ducation[\/vc_custom_heading][vc_column_text uncode_shortcode_id=\u00a0\u00bb189200″]Ind\u00e9pendamment des th\u00e9rapies sp\u00e9cifiques \u00e0 la maladie, les maladies concomitantes (par exemple, cataracte, \u0153d\u00e8me maculaire) doivent \u00eatre trait\u00e9es conform\u00e9ment aux directives. Parall\u00e8lement, la r\u00e9\u00e9ducation basse vision est centrale pour pr\u00e9server la mobilit\u00e9, la capacit\u00e9 de travail et la participation sociale. Les \u00e9tudes d\u00e9crivent une charge consid\u00e9rable au quotidien (psychosociale, professionnelle, \u00e9conomique) \u2013 la r\u00e9\u00e9ducation, les aides techniques et le conseil sont donc utiles pr\u00e9cocement.1<\/sup>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row row_height_percent=\u00a0\u00bb0″ override_padding=\u00a0\u00bbyes\u00a0\u00bb h_padding=\u00a0\u00bb2″ top_padding=\u00a0\u00bb3″ bottom_padding=\u00a0\u00bb3″ overlay_alpha=\u00a0\u00bb50″ gutter_size=\u00a0\u00bb3″ column_width_percent=\u00a0\u00bb100″ shift_y=\u00a0\u00bb0″ z_index=\u00a0\u00bb0″ content_parallax=\u00a0\u00bb0″ uncode_shortcode_id=\u00a0\u00bb137928″][vc_column width=\u00a0\u00bb1\/1″][vc_row_inner][vc_column_inner width=\u00a0\u00bb2\/3″][vc_custom_heading text_font=\u00a0\u00bbfont-714446″ text_size=\u00a0\u00bbfontsize-914237″ text_weight=\u00a0\u00bb300″ uncode_shortcode_id=\u00a0\u00bb270723″]Qu\u2019est-ce que cela signifie concr\u00e8tement pour les personnes concern\u00e9es ?[\/vc_custom_heading][\/vc_column_inner][vc_column_inner column_width_percent=\u00a0\u00bb100″ gutter_size=\u00a0\u00bb3″ overlay_alpha=\u00a0\u00bb50″ shift_x=\u00a0\u00bb0″ shift_y=\u00a0\u00bb0″ shift_y_down=\u00a0\u00bb0″ z_index=\u00a0\u00bb0″ medium_visibility=\u00a0\u00bbyes\u00a0\u00bb medium_width=\u00a0\u00bb0″ mobile_visibility=\u00a0\u00bbyes\u00a0\u00bb mobile_width=\u00a0\u00bb0″ width=\u00a0\u00bb1\/3″ uncode_shortcode_id=\u00a0\u00bb542260″][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner column_width_percent=\u00a0\u00bb100″ gutter_size=\u00a0\u00bb3″ overlay_alpha=\u00a0\u00bb50″ shift_x=\u00a0\u00bb0″ shift_y=\u00a0\u00bb0″ shift_y_down=\u00a0\u00bb0″ z_index=\u00a0\u00bb0″ medium_visibility=\u00a0\u00bbyes\u00a0\u00bb medium_width=\u00a0\u00bb0″ mobile_visibility=\u00a0\u00bbyes\u00a0\u00bb mobile_width=\u00a0\u00bb0″ width=\u00a0\u00bb1\/3″ uncode_shortcode_id=\u00a0\u00bb163215″][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb2\/3″][vc_column_text uncode_shortcode_id=\u00a0\u00bb179164″]<\/p>\n

    \n
  • D\u00e9finir des objectifs : souhaitez-vous pr\u00e9server la fonction, faciliter le quotidien ou les deux ? Parlez ouvertement de vos priorit\u00e9s.1<\/sup> <\/li>\n
  • Envisager la TES : si la fonction r\u00e9tinienne est pr\u00e9serv\u00e9e, la TES (par exemple avec OkuStim\u00ae) peut \u00eatre une option \u2013 avec une indication de ralentissement dose-d\u00e9pendant de la perte de VFA et une bonne tol\u00e9rance dans les \u00e9tudes.2,3<\/sup><\/li>\n
  • Th\u00e9rapie g\u00e9nique s\u00e9lective : v\u00e9rifiez les r\u00e9sultats g\u00e9n\u00e9tiques (par exemple, RPE65). Pour de nombreuses autres formes, les \u00e9tudes sont actuellement la passerelle vers de nouvelles th\u00e9rapies.1,4<\/sup> <\/li>\n
  • Penser de mani\u00e8re globale : la r\u00e9\u00e9ducation et les aides techniques (contraste\/\u00e9clairage, grossissement, orientation\/mobilit\u00e9, assistance num\u00e9rique) font partie int\u00e9grante de la prise en charge et peuvent stabiliser sensiblement la qualit\u00e9 de vie.1<\/sup><\/li>\n<\/ul>\n

    [\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row row_height_percent=\u00a0\u00bb0″ override_padding=\u00a0\u00bbyes\u00a0\u00bb h_padding=\u00a0\u00bb2″ top_padding=\u00a0\u00bb3″ bottom_padding=\u00a0\u00bb3″ overlay_alpha=\u00a0\u00bb50″ gutter_size=\u00a0\u00bb3″ column_width_percent=\u00a0\u00bb100″ shift_y=\u00a0\u00bb0″ z_index=\u00a0\u00bb0″ content_parallax=\u00a0\u00bb0″ uncode_shortcode_id=\u00a0\u00bb609480″][vc_column width=\u00a0\u00bb1\/1″][vc_separator uncode_shortcode_id=\u00a0\u00bb100849″ sep_color_type=\u00a0\u00bbuncode-solid\u00a0\u00bb sep_color_solid=\u00a0\u00bb#cddfed\u00a0\u00bb][vc_custom_heading heading_semantic=\u00a0\u00bbh6″ text_size=\u00a0\u00bbh4″ uncode_shortcode_id=\u00a0\u00bb493566″]R\u00e9f\u00e9rences[\/vc_custom_heading][vc_column_text text_lead=\u00a0\u00bbsmall\u00a0\u00bb uncode_shortcode_id=\u00a0\u00bb149335″]1 Cross N et al. Retinitis Pigmentosa: Burden of Disease and Current Unmet Needs. Clin Ophthalmol. 2022;16:1993\u20132010. <\/p>\n

    2 Stett A et al. Transcorneal electrical stimulation dose-dependently slows the visual field loss in RP. Transl Vis Sci Technol. 2023;12(2):29. <\/p>\n

    3 Jolly JK et al. Transcorneal Electrical Stimulation for the Treatment of Retinitis Pigmentosa: A Multicenter Safety Study (TESOLA). Ophthalmic Res. 2020;63(3):234\u2013243. <\/p>\n

    4 McClements ME et al. Optogenetic Gene Therapy for the Degenerate Retina: Recent Advances. Front Neurosci. 2020;14. <\/p>\n

    5 Allen PJ. Retinal prostheses: Where to from here? Clin Exp Ophthalmol. 2021;49:418\u2013429.[\/vc_column_text][\/vc_column][\/vc_row][vc_row row_height_percent=\u00a0\u00bb0″ override_padding=\u00a0\u00bbyes\u00a0\u00bb h_padding=\u00a0\u00bb2″ top_padding=\u00a0\u00bb3″ bottom_padding=\u00a0\u00bb3″ back_color=\u00a0\u00bbcolor-206913″ overlay_alpha=\u00a0\u00bb50″ gutter_size=\u00a0\u00bb3″ column_width_percent=\u00a0\u00bb100″ shift_y=\u00a0\u00bb0″ z_index=\u00a0\u00bb0″ content_parallax=\u00a0\u00bb0″ uncode_shortcode_id=\u00a0\u00bb118356″ back_color_type=\u00a0\u00bbuncode-palette\u00a0\u00bb][vc_column column_width_percent=\u00a0\u00bb100″ align_horizontal=\u00a0\u00bbalign_center\u00a0\u00bb gutter_size=\u00a0\u00bb4″ overlay_alpha=\u00a0\u00bb50″ shift_x=\u00a0\u00bb0″ shift_y=\u00a0\u00bb0″ shift_y_down=\u00a0\u00bb0″ z_index=\u00a0\u00bb0″ medium_width=\u00a0\u00bb0″ mobile_width=\u00a0\u00bb0″ width=\u00a0\u00bb1\/1″ uncode_shortcode_id=\u00a0\u00bb152446″][vc_custom_heading text_font=\u00a0\u00bbfont-714446″ text_size=\u00a0\u00bbfontsize-914237″ text_weight=\u00a0\u00bb300″ uncode_shortcode_id=\u00a0\u00bb109998″]Tout savoir sur la th\u00e9rapie,
    \nla recherche clinique et Okuvision[\/vc_custom_heading][vc_row_inner][vc_column_inner width=\u00a0\u00bb1\/1″][uncode_index el_id=\u00a0\u00bbindex-974899″ index_type=\u00a0\u00bbcarousel\u00a0\u00bb loop=\u00a0\u00bbsize:3|order_by:date|post_type:post|categories:110|taxonomy_count:10″ carousel_lg=\u00a0\u00bb3″ carousel_md=\u00a0\u00bb2″ carousel_sm=\u00a0\u00bb1″ thumb_size=\u00a0\u00bbsixteen-nine\u00a0\u00bb gutter_size=\u00a0\u00bb3″ post_items=\u00a0\u00bbmedia|featured|onpost|original,date,title|-,text|excerpt|200,category|colorbg|relative|display-icon\u00a0\u00bb carousel_height=\u00a0\u00bbequal\u00a0\u00bb carousel_interval=\u00a0\u00bb3000″ carousel_navspeed=\u00a0\u00bb400″ advanced_nav=\u00a0\u00bbyes\u00a0\u00bb el_id1=\u00a0\u00bbindex-974899″ stage_padding=\u00a0\u00bb0″ single_back_color=\u00a0\u00bbcolor-942029″ single_overlay_opacity=\u00a0\u00bb50″ single_padding=\u00a0\u00bb2″ single_title_dimension=\u00a0\u00bbh4″ single_border=\u00a0\u00bbyes\u00a0\u00bb uncode_shortcode_id=\u00a0\u00bb186887″][uncode_carousel_nav padding=\u00a0\u00bb0″ h_align=\u00a0\u00bbcenter\u00a0\u00bb hide_arrows=\u00a0\u00bbyes\u00a0\u00bb dots_style=\u00a0\u00bblines\u00a0\u00bb hide_counter=\u00a0\u00bbyes\u00a0\u00bb uncode_shortcode_id=\u00a0\u00bb207978″ target=\u00a0\u00bbindex-974899″ dot_single_width=\u00a0\u00bb12″ dot_single_active=\u00a0\u00bb24″ dot_single_height=\u00a0\u00bb12″ dot_single_radius=\u00a0\u00bb999″][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

    [vc_row unlock_row_content=\u00a0\u00bbyes\u00a0\u00bb row_height_percent=\u00a0\u00bb0″ override_padding=\u00a0\u00bbyes\u00a0\u00bb h_padding=\u00a0\u00bb0″ top_padding=\u00a0\u00bb0″ bottom_padding=\u00a0\u00bb0″ back_color=\u00a0\u00bbcolor-206913″ overlay_alpha=\u00a0\u00bb50″ gutter_size=\u00a0\u00bb3″ column_width_percent=\u00a0\u00bb100″ shift_y=\u00a0\u00bb0″ z_index=\u00a0\u00bb0″ content_parallax=\u00a0\u00bb0″ uncode_shortcode_id=\u00a0\u00bb126459″ back_color_type=\u00a0\u00bbuncode-palette\u00a0\u00bb][vc_column width=\u00a0\u00bb1\/1″][\/vc_column][\/vc_row][vc_row row_height_percent=\u00a0\u00bb0″ override_padding=\u00a0\u00bbyes\u00a0\u00bb h_padding=\u00a0\u00bb2″ […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-2670","page","type-page","status-publish","hentry"],"yoast_head":"\nR\u00e9tinite pigmentaire : options th\u00e9rapeutiques et preuves<\/title>\n<meta name=\"description\" content=\"La th\u00e9rapie de la RP expliqu\u00e9e : objectifs, options, preuves relatives \u00e0 la TES (OkuStim\u00ae), distinction par rapport \u00e0 la th\u00e9rapie g\u00e9nique et \u00e0 la r\u00e9\u00e9ducation. Prochaines \u00e9tapes pour les personnes concern\u00e9es.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/okuvision.de\/fr\/retinitis-pigmentosa-therapie\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Th\u00e9rapie et traitement\" \/>\n<meta property=\"og:description\" content=\"La th\u00e9rapie de la RP expliqu\u00e9e : objectifs, options, preuves relatives \u00e0 la TES (OkuStim\u00ae), distinction par rapport \u00e0 la th\u00e9rapie g\u00e9nique et \u00e0 la r\u00e9\u00e9ducation. Prochaines \u00e9tapes pour les personnes concern\u00e9es.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/okuvision.de\/fr\/retinitis-pigmentosa-therapie\/\" \/>\n<meta property=\"og:site_name\" content=\"Okuvision\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-21T11:47:56+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/okuvision.de\\\/fr\\\/retinitis-pigmentosa-therapie\\\/\",\"url\":\"https:\\\/\\\/okuvision.de\\\/fr\\\/retinitis-pigmentosa-therapie\\\/\",\"name\":\"R\u00e9tinite pigmentaire : options th\u00e9rapeutiques et preuves\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/okuvision.de\\\/fr\\\/#website\"},\"datePublished\":\"2025-10-22T08:40:05+00:00\",\"dateModified\":\"2026-05-21T11:47:56+00:00\",\"description\":\"La th\u00e9rapie de la RP expliqu\u00e9e : objectifs, options, preuves relatives \u00e0 la TES (OkuStim\u00ae), distinction par rapport \u00e0 la th\u00e9rapie g\u00e9nique et \u00e0 la r\u00e9\u00e9ducation. Prochaines \u00e9tapes pour les personnes concern\u00e9es.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/okuvision.de\\\/fr\\\/retinitis-pigmentosa-therapie\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/okuvision.de\\\/fr\\\/retinitis-pigmentosa-therapie\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/okuvision.de\\\/fr\\\/retinitis-pigmentosa-therapie\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/okuvision.de\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Th\u00e9rapie et traitement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/okuvision.de\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/okuvision.de\\\/fr\\\/\",\"name\":\"Okuvision\",\"description\":\"\u2013 Sehen erhalten\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/okuvision.de\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"R\u00e9tinite pigmentaire : options th\u00e9rapeutiques et preuves","description":"La th\u00e9rapie de la RP expliqu\u00e9e : objectifs, options, preuves relatives \u00e0 la TES (OkuStim\u00ae), distinction par rapport \u00e0 la th\u00e9rapie g\u00e9nique et \u00e0 la r\u00e9\u00e9ducation. Prochaines \u00e9tapes pour les personnes concern\u00e9es.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/okuvision.de\/fr\/retinitis-pigmentosa-therapie\/","og_locale":"fr_FR","og_type":"article","og_title":"Th\u00e9rapie et traitement","og_description":"La th\u00e9rapie de la RP expliqu\u00e9e : objectifs, options, preuves relatives \u00e0 la TES (OkuStim\u00ae), distinction par rapport \u00e0 la th\u00e9rapie g\u00e9nique et \u00e0 la r\u00e9\u00e9ducation. Prochaines \u00e9tapes pour les personnes concern\u00e9es.","og_url":"https:\/\/okuvision.de\/fr\/retinitis-pigmentosa-therapie\/","og_site_name":"Okuvision","article_modified_time":"2026-05-21T11:47:56+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/okuvision.de\/fr\/retinitis-pigmentosa-therapie\/","url":"https:\/\/okuvision.de\/fr\/retinitis-pigmentosa-therapie\/","name":"R\u00e9tinite pigmentaire : options th\u00e9rapeutiques et preuves","isPartOf":{"@id":"https:\/\/okuvision.de\/fr\/#website"},"datePublished":"2025-10-22T08:40:05+00:00","dateModified":"2026-05-21T11:47:56+00:00","description":"La th\u00e9rapie de la RP expliqu\u00e9e : objectifs, options, preuves relatives \u00e0 la TES (OkuStim\u00ae), distinction par rapport \u00e0 la th\u00e9rapie g\u00e9nique et \u00e0 la r\u00e9\u00e9ducation. Prochaines \u00e9tapes pour les personnes concern\u00e9es.","breadcrumb":{"@id":"https:\/\/okuvision.de\/fr\/retinitis-pigmentosa-therapie\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/okuvision.de\/fr\/retinitis-pigmentosa-therapie\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/okuvision.de\/fr\/retinitis-pigmentosa-therapie\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/okuvision.de\/fr\/"},{"@type":"ListItem","position":2,"name":"Th\u00e9rapie et traitement"}]},{"@type":"WebSite","@id":"https:\/\/okuvision.de\/fr\/#website","url":"https:\/\/okuvision.de\/fr\/","name":"Okuvision","description":"\u2013 Sehen erhalten","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/okuvision.de\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"}]}},"_links":{"self":[{"href":"https:\/\/okuvision.de\/fr\/wp-json\/wp\/v2\/pages\/2670","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/okuvision.de\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/okuvision.de\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/okuvision.de\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/okuvision.de\/fr\/wp-json\/wp\/v2\/comments?post=2670"}],"version-history":[{"count":9,"href":"https:\/\/okuvision.de\/fr\/wp-json\/wp\/v2\/pages\/2670\/revisions"}],"predecessor-version":[{"id":2967,"href":"https:\/\/okuvision.de\/fr\/wp-json\/wp\/v2\/pages\/2670\/revisions\/2967"}],"wp:attachment":[{"href":"https:\/\/okuvision.de\/fr\/wp-json\/wp\/v2\/media?parent=2670"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}